Stocktaking: A selection of Lancet Research on April 4, 2020

Guselkumab for active psoriasis arthritis (DISCOVER-1 study)DOI: https://doi.org/10.1016/S0140-6736 (20) 30265-8many psoriasis patients are not responding adequately to tumor necrosis factor (TNF) inhibitorsGuselkumab is a leukin-23 (IL-23)-specific inhibitor that significantly improved the symptoms and signs of psoriasis arthritis in Phase II trialsRecently, researchers published the results of their Phase III clinical studyPatients with active psoriasis were involved in the study, with at least three swollen and three painful joints, C-reactive protein s.0.3 mg/dL, and at least 4 months of apster, at least 3 months of non-biological disease modified anti-rheumatic drugs (DMARDs) or at least 4 weeks of nonsteroidal anti-inflammatory drugsAbout 30% of the study participants may have previously received 1-2 TNF inhibitorsPatients were randomly given 100mg Guselkumab every 4 weeks, 100mg Gukumselab 1 injected at the 0th and 4th weeks, followed by a placebo every 8 weeks or every 8 weeksThe main endpoint of the study was the 24-week rate of improvement in the disease symptoms of the American Society of Rheumatology (ACR20) in patients381 patients participated in the study, of which 128 were taken every 4 weeks in the Guselkumab group, 127 in the Guselkumab group every eight weeks and 126 in the placebo group362 patients completed 24 weeks of treatmentCompared to the placebo group (66/127), there was a significant increase in ACR20 in patients in the Guselkumab treatment group (76/128) and the treatment group (66/127) every 4 weeks, with a 37% difference in the 4 weeks treatment group and 30% in the 8 weeks group compared to the placeboAt 24 weeks, Guselkumab did not have a serious adverse event in the treatment group every 4 weeks, 4 patients per 8 weeks and 5 patients in the placebo groupOne patient in the placebo group died of heart failure and two patients developed severe infections;2: Guselkumab treats active psoriasis arthritis (DISCOVER-2) DOI: https://doi.org/10.1016/S0140-6736 (20) 30263-4 leukocyte interleukin 23 (IL-23)/T-helper 17 cell pathways associated with the pathogenesis of psoriasis arthritis." Guselkumab can specifically bind to IL-23p19 sub-base, inhibiting the IL-23 pathway In the Phase II study, Guselkumab significantly and safely improved symptoms in patients with psoriasis arthritis, and researchers recently published the results of the Phase III DISCOVER-2 study patients with active psoriasis without biological therapy, patients still had at least 5 swollen joints, at least 5 painful joints, and C-reactive protein s.6mg/dL after receiving standard therapy Patients were randomly injected with 100mg of guselkumab every 4 weeks, 100mg guselkumab 100mg at the 0th and 4th weeks, and then once every 8 weeks or placebo The main endpoint of the study was 20% (ACR20) improvement at the American Society of Rheumatology in the 24weeks 741 patients were randomly divided into 4 weeks (n-246), 8-week group (n-248) or placebo group (n-247) , 716 cases were treated continuously to 24 weeks Compared to the placebo group (81 out of 246 people, 33%), the proportion of patients in the guselkumab group per 4 week (156 out of 245, 64%) and every 8 weeks group (159 out of 248 people, 64%) increased significantly in the proportion of patients who achieved the ACR20 response in week 24 (31% of the percentage difference between the 4 weeks group and the placebo group was 31% per 8 weeks) As of week 24, 8 of the 245 patients in the 4 week group received guselkumab had severe adverse events (3 cases of severe infection), 3 of the 248 patients in the 8 weeks group receiving guselkumab (1% had severe adverse events (1 case of severe infection), and 7 of the 246 patients receiving a placebo had severe adverse events (3%) with no deaths 3: The first locally transmitted of corolla pneumonia in the United States
DOI: https://doi.org/10.1016/S0140-6736 (20) 30607-3 2019 coronavirus disease (COVID-19) is an infectious disease caused by Severe Acute Respiratory Syndrome (SARS-CoV-2), first discovered in China in December 2019 In January 2020, the first case of COVID-19 was detected by state, local and federal public health agencies in Illinois confirmed COVID-19 patients are defined as patients who tested positive for SARS-CoV-2 Contactists are people who come into contact with COVID-19 patients on or after the onset of symptoms Contacters were monitored for positive symptoms 14 days after the last contact Contacts with fever, cough or shortness of breath were targeted and tested for SARS-CoV-2 Thirty-two asymptomatic health care workers were also tested first confirmed patient (patient 1) was a woman in her 60s who returned from China in mid-January 2020 A week later, she was hospitalized with pneumonia and tested positive for SARS-CoV-2 Her husband,2, who has no history of travel in China but has close contact with his wife, was admitted to hospital eight days later and tested positive for SARS-CoV-2 A total of 372 contacts were found, 347 were actively monitored for symptoms, including 152 cases of community contacts and 195 cases of health care workers Of those who were monitored, 43 were subjected to the subject, in addition to patient No 2 The SARS-CoV-2 tests of all 43 of the above-mentioned respondents and all 32 asymptomatic health care workers were negative Source: MedSci Original